Bristol-Myers Squibb Reports Results of Opdivo (nivolumab) in P-III CheckMate-459 Study as 1L Treatment for Patients with Unresectable Hepatocellular Carcinoma
Shots:
- The P-III CheckMate-459 study results involve assessing of Opdivo vs sorafenib as a 1L treatment in patients with unresectable hepatocellular carcinoma (HCC)
- The P-III CheckMate-459 study results demonstrated that it did not meet its 1EPs of overall survival (OS) per the pre-specified analysis- no new safety signals were observed
- Opdivo is PD-1 immune check inhibitor- harnessing the body’s own immune system to help restore anti-tumor immune response- being evaluated in multiple studies for HCC as monothx. or in combination with Yervoy (ipilimumab) for prior treated patients
Click here to read full press release/ article | Ref: BMS | Image: Record Journal
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com